Mitsubishi Tanabe Pharma plans to purchase Medicago for $357m
Based on the terms of the definitive agreement, the acquirer will purchase all of the issued and outstanding common shares of Medicago for $1.16 per share in cash,
Summit Therapeutics’ partner Akeso has secured China’s National Medical Products Administration (NMPA) authorisation for the use of ivonescimab in combination with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer (NSCLC) patients.
The recalled prescription only medicines include Erythromycin, Metformin, Atenolol, Pramipexole, Risperidone and Clopidogrel among others. MHRA Inspection, Enforcement and Standards director Gerald Heddell said that the move was
Simplifying testing and increasing performance of the process, the new capsules remove the need for costly, incompetent pooling of multiple batches for primary separations/prefiltration, secondary clarification, cell culture